235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (235)
- Addiction (5)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (3)
- Bone & Muscle (2)
- Cancer (11)
- COVID-19 (Coronavirus) (8)
- Diabetes (7)
- Ear, Nose and Throat (7)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (2)
- Healthy Volunteers (45)
- Heart Disease (20)
- Infectious Disease (11)
- Liver Disease (13)
- Lung Disease (2)
- Neurological Disorders (31)
- Nutrition (2)
- Obesity (9)
- Obstetrics & Gynecology (10)
- Pediatrics (17)
- Psychiatric Disorders (7)
- Rehabilitation (2)
- Stroke (2)
- Transplant (12)
- Vascular Conditions (1)
Displaying 1 - 3 of 3
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Meyer Kattan, MD
Status: Currently Recruiting
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If…
Condition: Ear, Nose and Throat / Hearing Loss
Investigator: Justin Golub, MD, MS
Status: Currently Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a study to obtain information on how a hearing aid-based intervention can prevent cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). Age-related hearing loss (ARHL) is the third most common chronic condition in older adults. The…
Condition: Ear, Nose and Throat / Hearing Loss
Investigator: Nima Mesgarani, PhD
Status: Currently Recruiting
The purpose of this study is to learn more about the mechanisms of hearing loss, specifically to learn how abnormalities in the brain may produce certain experiences that are common in patients with hearing loss. Individuals with hearing loss will be compared to individuals with normal hearing.